NEW YORK (Reuters Health) Mar 20 – The use of HMG-coenzyme A reductase inhibitors (statins) is associated with a substantial reduction in fracture risk in older women , according to a report in the March 11th issue of the Archives of Internal Medicine. The effects of bone mineral density (BMD) do not explain this risk reduction.
In a cross-sectional study, Dr. Julie A. Pasco and colleagues from the University of Melbourne, Australia, examined the association between statin use, fracture risk, and BMD in 573 women with incident fractures and 802 women without fracture. The patients were aged 50 to 95, with an average of about 70 years.
The subjects completed questionnaires regarding medication use and lifestyle factors. Univariate analysis showed an odds ratio for fracture associated with statin use of 0.40. After adjusting for BMD, the odds ratio for fracture at the femoral neck, spine, and for the whole body changed only slightly to 0.45, 0.42, and 0.43, respectively.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!